Your browser doesn't support javascript.
Outcomes of SARS-CoV-2 infection in cancer versus non-cancer-patients: A population-based study in northeastern Italy.
Rugge, Massimo; Zorzi, Manuel; Guzzinati, Stefano; Stocco, Carmen; Avossa, Francesco; Del Zotto, Stefania; Clagnan, Elena; Bricca, Ludovica; Dal Maso, Luigino; Serraino, Diego.
  • Rugge M; Department of Medicine - DIMED, Surgical Pathology and Cytopathology Unit, Università degli Studi di Padova, Padova, Italy.
  • Zorzi M; Veneto Tumour Registry, Azienda Zero, Padova, Italy.
  • Guzzinati S; Veneto Tumour Registry, Azienda Zero, Padova, Italy.
  • Stocco C; Veneto Tumour Registry, Azienda Zero, Padova, Italy.
  • Avossa F; Veneto Tumour Registry, Azienda Zero, Padova, Italy.
  • Del Zotto S; Regional Epidemiological Service Unit, Azienda Zero, Padova, Italy.
  • Clagnan E; Friuli Venezia Giulia Regional Health Coordination Agency, Udine, Italy.
  • Bricca L; Friuli Venezia Giulia Regional Health Coordination Agency, Udine, Italy.
  • Dal Maso L; Department of Medicine - DIMED, Surgical Pathology and Cytopathology Unit, Università degli Studi di Padova, Padova, Italy.
  • Serraino D; Cancer Epidemiology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.
Tumori ; : 3008916211073771, 2022 Feb 08.
Article in English | MEDLINE | ID: covidwho-1673723
ABSTRACT

INTRODUCTION:

This study assesses the risk of infection and clinical outcomes in a large consecutive population of cancer and non-cancer patients tested for SARS-CoV-2 status.

METHODS:

Study patients underwent SARS-CoV-2 molecular-testing between 22 February 2020 and 31 July 2020, and were found infected (CoV2+ve) or uninfected. History of malignancy was obtained from regional population-based cancer registries. Cancer-patients were distinguished by time between cancer diagnosis and SARS-CoV-2 testing (<12/⩾12 months). Comorbidities, hospitalization, and death at 15 September 2020 were retrieved from regional population-based databases. The impact of cancer history on SARS-CoV-2 infection and clinical outcomes was calculated by fitting a multivariable logistic regression model, adjusting for sex, age, and comorbidities.

RESULTS:

Among 552,362 individuals tested for SARS-CoV-2, 55,206 (10.0%) were cancer-patients and 22,564 (4.1%) tested CoV2+ve. Irrespective of time since cancer diagnosis, SARS-CoV-2 infection was significantly lower among cancer patients (1,787; 3.2%) than non-cancer individuals (20,777; 4.2% - Odds Ratio (OR)=0.60; 0.57-0.63). CoV2+ve cancer-patients were older than non-cancer individuals (median age 77 versus 57 years; p<0.0001), were more frequently men and with comorbidities. Hospitalizations (39.9% versus 22.5%; OR=1.61; 1.44-1.80) and deaths (24.3% versus 9.7%; OR=1.51; 1.32-1.72) were more frequent in cancer-patients. CoV2+ve cancer-patients were at higher risk of death (lung OR=2.90; 1.58-5.24, blood OR=2.73; 1.88-3.93, breast OR=1.77; 1.32-2.35).

CONCLUSIONS:

The risks of hospitalization and death are significantly higher in CoV2+ve individuals with past or present cancer (particularly malignancies of the lung, hematologic or breast) than in those with no history of cancer.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Tumori Year: 2022 Document Type: Article Affiliation country: 03008916211073771

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Tumori Year: 2022 Document Type: Article Affiliation country: 03008916211073771